Updates

THRU ONLINE FILING July 14, 2026 BSE Ltd. National Stock Exchange India Limited, Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block-G, Dalal Street Bandra Kurla Complex, Bandra - (East) Mumbai 400 023 Mumbai 400 051 Scrip Code - 524494 Scrip Code: IPCALAB Sub: Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 Ref: Regulation 34 (2) (f) of SEBI (LODR) Regulations, 2015. Dear Sir/Madam, Please find attached herewith the Business Responsibility and Sustainability Report (BRSR) forming part of the Annual Report of the Company for the financial year 2025-26. Kindly acknowledge the receipt. Thanking you Yours faithfully For Ipca Laboratories Limited Harish P. Kamath Corporate Counsel & Company Secretary Encl: a/a ANNEXURE 6 BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT [BRSR] SECTION A - GENERAL DISCLOSURE I. Details of the listed entity 1 Corporate Identity Number (CIN) of the Listed Entity L24239MH1949PLC007837 2 Name of the Listed Entity Ipca Laboratories Limited 3 Year of incorporation 1949 4 Registered office address 48, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067, Maharashtra, India 5 Corporate address 125, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067, Maharashtra, India 6 E-mail investors@ipca.com 7 Telephone 91-22-62105000 8 Website https://www.ipca.com/ 9 Financial year for which reporting is being done April 1, 2025 to March 31, 2026 10 Name of the Stock Exchange(s) where shares are listed BSE, NSE 11 Paid-up Capital Rs. 25.37 Crores 12 Name and contact details (telephone, email address) of the Mr. Ajit Kumar Jain person who may be contacted in case of any queries on the Managing Director BRSR report 022-6210 6020 ajit.jain@ipca.com 13 Reporting Boundary Standalone 14 Name of assurance provider SGS India Private Limited 15 Type of assurance obtained BRSR Core – Reasonable assurance Remaining part of BRSR – Limited assurance II Products and Services 1 Details of business activities (accounting for 90% of the turnover): Sr. No. Description of Main Activity Description of Business Activity % of Turnover of the entity 1 Manufacture of Pharmaceuticals Development, Manufacturing and 100% Marketing of Pharmaceuticals Products 2 Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Sr. No. Product NIC Code % of Turnover of the entity 1 Manufacture of Pharmaceuticals 21002 100% III Operations 1 Number of locations where plants and/or operations/offices of the entity are situated Location Number of plants Number of offices Total National 16 5 21 International 2 7 9 2 Markets served by the entity A Number of locations Locations Total National (No. of States) Pan-India International (No. of Countries) More than 100 B What is the contribution of exports as a percentage of the total turnover of the entity? Over 42% of the company’s total revenue ( standalone ) can be attributed to its earning from exports. C A brief on types of customers Our customers include wholesalers, distributors, pharmacy chains, hospitals, government institutions and other pharmaceutical companies. Annual Report 2025-26 IV Employees 1 Details as at the end of Financial Year: A Employees and workers (including differently abled) Male Female Particulars Total (A) No. (B) % (B / A) No. (C) % (C / A) Employees Permanent 16,052 15,010 93.51 1,042 6.49 Other than permanent 592 476 80.41 116 19.59 Total Employees 16,644 15,486 93.04 1,158 6.96 Workers Permanent 1,158 1,155 99.74 3 0.26 Other than permanent 5,665 5,345 94.35 320 5.65 Total Workers 6,823 6,500 95.27 323 4.73 B Differently abled Employees and workers: Male Female Particulars Total (A) No. (B) % (B / A) No. (C) % (C / A) Differently abled Employees Permanent 2 2 100 - - Other than permanent - - - - - Total Employees 2 2 100 - - Differently abled Workers Permanent - - - - - Other than permanent - - - - - Total Workers - - - - - 2 Participation/Inclusion/Representation of women Particulars Total (A) Numbers of Female (B) % of Female (B / A) Board of Directors 8 1 12.50% Key Management Personnel 5 0 0.00% 3 Turnover rate for permanent employees and workers (Disclose trends for the past 3 years) Particulars FY 25-26 FY 24-25 FY 23-24 Male Female Total Male Female Total Male Female Total Permanent Employees 27.7% 20.0% 27.2% 25.4% 23.1% 25.2% 23.3% 18.8% 23.0% Permanent Workers 3.6% - 3.6% 4.7% - 4.7% 3.9% - 3.9% V Holding, Subsidiary and Associate Companies (including joint ventures) Names of holding / subsidiary / associate companies / joint ventures Sr. Name of the holding /subsidiary / associate Indicate whether % of shares held Does the entity indicated No. companies / joint ventures (A) holding/ by listed entity at column A, participate in Subsidiary/ the Business Responsibility Associate/ Joint initiatives of the listed Venture entity? (Yes/No) 1 Ipca Pharmaceuticals Inc. USA Subsidiary 100% Yes 2 Ipca Laboratories (U.K.) Ltd. Subsidiary 100% Yes 3 Ipca Pharma Nigeria Ltd. Subsidiary 100% Yes 4 Ipca Pharma (Australia) Pty.Ltd Subsidiary 100% Yes 5 Onyx Scientific Ltd. U.K Subsidiary 100% Yes 6 Pisgah Laboratories Inc. USA Subsidiary 100% Yes 7 Ipca Pharmaceuticals GmbH, Germany Subsidiary 100% Yes Sr. Name of the holding /subsidiary / associate Indicate whether % of shares held Does the entity indicated No. companies / joint ventures (A) holding/ by listed entity at column A, participate in Subsidiary/ the Business Responsibility Associate/ Joint initiatives of the listed Venture entity? (Yes/No) 8 Ipca Pharma (NZ) Pty. Ltd. (Subsidiary of Ipca Subsidiary 100% Yes Pharma (Australia) Pty.Ltd.) 9 Ipca Foundation* Subsidiary 100% Yes 10 Trophic Wellness Pvt. Ltd. Subsidiary 58.88% Yes 11 Unichem Laboratories Ltd Subsidiary 52.67% Yes 12 Niche Generics Ltd., UK Subsidiary 100% Yes 13 Unichem SA Pty Ltd., South Africa Subsidiary 100% Yes 14 Unichem Farmaceutica Do Brasil Ltda, Brazil Subsidiary 100% Yes 15 Unichem Pharmaceuticals USA Inc., USA Subsidiary 100% Yes 16 Unichem Laboratories Ltd., Ireland Subsidiary 100% Yes 17 Unichem (China) Pvt. Ltd., China Subsidiary 100% Yes 18 Avik Pharmaceutical Ltd. Joint Venture 50% Yes 19 Lyka Labs Ltd. (w.e.f. 24.11.2021) Joint Venture 40.98% Yes 20 Krebs Biochemicals & Industries Ltd. Associate 49.65% Yes *Company limited by guarantee. Incorporated for CSR purpose. VI CSR Details Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes A Turnover (in `) 7431.39 Crores B Net worth (in `) 7979.35 Crores VII Transparency and Disclosures Compliances Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct Stakeholder group Grievance Redressal FY 25-26 FY 24-25 from whom complaint Mechanism in Place Number of Number of Remarks Number of Number of Remarks is received (Yes/No) (If Yes, then complaints complaints complaints complaints provide web-link for filed during pending filed during pending grievance redress the year resolution at the year resolution at policy) close of the close of the year year Communities Yes* - - - - Investors (other than Yes* - - - - shareholders) Shareholders Yes* 22 - 21 - Employees and workers Yes* - - - - Customers Yes* 877 29 796 3 Value Chain Partners Yes* - - - - Other Yes* - - - - The complaints include packaging defects such as missing components, damaged label and damaged outer packaging. *Web-link for Grievance Redressal Policy Internal Stakeholders: https://www.ipca.com/wp-content/pdf/corporate-policy/2023/ Grievance-Redressal-Internal-Policy.pdf *Web-link for Grievance Redressal Policy External Stakeholders: https://www.ipca.com/wp-content/pdf/corporate-policy/2023/ Grievance-Redressal-External-Policy.pdf Annual Report 2025-26 Overview of the entity’s material responsible business conduct issues Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social matters that present a risk or an opportunity to you [Showing first 8,000 characters — download PDF for full document]